Teva Study Finds Only 23% of Younger Adults with Mood Disorders and Tardive Dyskinesia (TD) Symptoms Are Formally Diagnosed with TD Despite Widespread Impact

A new analysis from the IMPACT-TD Registry, conducted by Teva, has found that tardive dyskinesia (TD) imposes a significant burden on individuals who also live with mood disorders. The study indicates that the condition impacts the lives of patients across various age groups, highlighting a widespread effect on those managing concomitant mental health conditions. The findings suggest that the physical movements associated with TD can create substantial challenges for patients already navigating the complexities of mood-related illnesses.^[1][2]

Specifically focusing on young adults between the ages of 18 and 29, the data shows that 85% of those experiencing TD movements report a moderate to severe impact on their daily lives. This demographic, which included a sample size of 13 individuals in the registry, faces a high level of impairment that affects their overall well-being. Despite the severity of these symptoms and their impact on daily functioning, the study found that only 23% of these individuals had received a formal medical diagnosis for the condition.^[1][2]

The discrepancy between the prevalence of symptoms and the rate of formal diagnosis suggests a potential gap in clinical recognition for younger patients. While the impact of TD is widespread regardless of age, the low diagnosis rate among young adults underscores the need for increased awareness and screening within this specific population. The IMPACT-TD Registry continues to provide data on how these involuntary movements affect the quality of life for those with mood disorders.^[1][2]